Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | RBP4 | P02753 | 1/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LCAT | P04180 | 1/20 | 0.48 |
| ▸ | IDH2 | P48735 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971605 | 0.88 | ADRB1 (0.57) | KDM4ECYP2C19ADRB1RBP4CHRM4 | |
| SCHEMBL13485751 | 0.86 | CHRM4 (0.59) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL2328007 | 0.83 | ADRB1 (0.54) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL5463427 | 0.83 | ADRB1 (0.64) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL2330983 | 0.82 | ADRB1 (0.53) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL8354208 | 0.81 | ADRB1 (0.78) | KDM4EADRB1RBP4PKMSLC6A7 | |
| SCHEMBL5232026 | 0.81 | SLC6A7 (0.68) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL1728756 | 0.80 | CHRM4 (0.59) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL1994796 | 0.80 | ADRB1 (0.64) | KDM4EADRB1RBP4CHRM4PKM | |
| SCHEMBL14923154 | 0.80 | ADRB1 (0.64) | KDM4EADRB1RBP4PKMSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| EP-2560978-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| EP-2048132-A1 | Tetrahydro-naphthalene and urea derivatives | Xention Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-1670761-B1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | XENTION LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KDM4E 804/4885CYP2C19 467/4885ADRB1 362/4885 |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | KDM4E 715/4885CYP2C19 205/4885ADRB1 2327/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KDM4E 804/4885CYP2C19 467/4885ADRB1 362/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | KDM4E 3911/4885CYP2C19 430/4885ADRB1 3600/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KDM4E 804/4885CYP2C19 467/4885ADRB1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.